No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention

Journal of Psychopharmacology

Volumn 20, Issue 6, 2006, Pages 789-798

  Oranje, B ^a   Gispen De Wied, C C ^b   Westenberg, H G M ^b   Kemner, C ^b   Verbaten, M N ^c   Kahn, R S ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Auditory oddball task; Bromocriptine; Dopamine; l dopa; P300; Processing negativity; Selective attention

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; HOMOVANILLIC ACID; LEVODOPA; PLACEBO; PROLACTIN;

ADULT; ARTICLE; AUDITORY STIMULATION; CONTROLLED STUDY; DEFENSE MECHANISM; DICHOTIC LISTENING; DIZZINESS; DOPAMINERGIC ACTIVITY; EVOKED RESPONSE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; P300 AMPLITUDE; PREPULSE INHIBITION; PRIORITY JOURNAL; PROCESSING NEGATIVITY; PSYCHOPHYSIOLOGY; SCHIZOPHRENIA; SELECTIVE ATTENTION; STARTLE REFLEX; STIMULUS RESPONSE; STRIATE CORTEX; TASK PERFORMANCE;

ADULT; ANTIPARKINSON AGENTS; ATTENTION; BROMOCRIPTINE; CROSS-OVER STUDIES; DOPAMINE; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; ELECTROOCULOGRAPHY; EVENT-RELATED POTENTIALS, P300; HOMOVANILLIC ACID; HUMANS; LEVODOPA; MALE; PROLACTIN; PSYCHOMOTOR PERFORMANCE; PSYCHOPHYSIOLOGY; RECEPTORS, DOPAMINE D2;

EID: 33750310053     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106061712     Document Type: Article

References (62)

1. Abduljawad K A, Langley R W, Bradshaw C M, Szabadi E (1998) Effects of bromocriptine and haloperidol on prepulse inhibition of the acoustic startle response in man. J Psychopharmacol 12: 239-245
2. Abduljawad K A, Langley R W, Bradshaw C M, Szabadi E (1999) Effects of bromocriptine and haloperidol on prepulse inhibition: comparison of the acoustic startle eyeblink response and the N1/P2 auditory-evoked response in man. J Psychopharmacol 13: 3-9
3. Ahveninen J, Jaaskelainen I P, Pennanen S, Liesivuori J, Ilmoniemi R J, Kahkonen S (2003) Auditory selective attention modulated by tryptophan depletion in humans. Neurosci Lett 340: 181-184
4. Andreasen N C, Flaum M, Arndt S (1992) The comprehensive assessment of symptoms and history (CASH): an instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry 49: 615-623
5. Antal A, Keri S, Bodis-Wollner I (1997) Dopamine D2 receptor blockade alters the primary and cognitive components of visual evoked potentials in the monkey, Macaca fascicularis. Neurosci Lett 232: 179-181
6. Baribeau-Braun J, Picton T W, Gosselin J Y (1983) Schizophrenia: a neurophysiological evaluation of abnormal information processing. Science 219: 874-876
7. Boutros N N, Nasrallah H, Leighty R, Torello M (1997) Auditory evoked potentials, clinical vs research applications. Psychiatry Res 69: 183-195
8. Cedarbaum J M, Kutt H, McDowell F H (1989) A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Neurology 39: 38-44
9. Clark C R, Geffen G M, Geffen L B (1987) Catecholamines and attention: II. Pharmacological studies in normal humans. Neurosci Biobehav Rev 11: 353-364
10. Coburn K L, Shillcutt S D, Tucker K A, Estes K M, Brin F B, Merai P, Moore N C (1998) P300 delay and attenuation in schizophrenia: reversal by neuroleptic medication. Biol Psychiatry 44: 466-474
11. del Pozo E, Schluter K, Nuesch E, Rosenthaler J, Kerp L (1986) Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. Eur J Clin Pharmacol 29: 615-618
12. Dempski R E, Scholtz E C, Oberholtzer E R, Yeh K C (1989) Pharmaceutical design and development of a Sinemet controlled-release formulation. Neurology 39: 20-24
13. Drewe J, Mazer N, Abisch E, Krummen K, Keck M (1988) Differential effect of food on kinetics of bromocriptine in a modified release capsule and a conventional formulation. Eur J Clin Pharmacol 35: 535-541
14. Duncan G E, Sheitman B B, Lieberman J A (1999) An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 29: 250-264
15. Endicott J, Spitzer R L (1978) A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35: 837-844
16. Frazer A E, Molinoff P B E, Winokur A E (1994) Biological Bases of Brain Function and Disease. Raven Press, New York, NY
17. Friedman D (1991) Endogenous scalp-recorded brain potentials in schizophrenia: a methodological review. In Steinhauer S R, Gruzelier J H, Zubin J (eds), Neuropsychology, Psychophysiology, and Information Processing. Elsevier Science Publishing Co., Amsterdam, pp. 91-127
18. Frodl Bauch T, Bottlender R, Hegerl U (1999a) Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology 40: 86-94
19. Frodl Bauch T, Gallinat J, Meisenzahl E M, Moller H J, Hegerl U (1999b) P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biol Psychiatry 45: 116-126
20. Green M F (1998) Schizophrenia from a Neurocognitive Perspective: Probing the Impenetrable Darkness. Allyn and Bacon, Inc., Boston, MA, pp. xii, 190
21. Iwanami A, Isono H, Okajima Y, Noda Y, Kamijima K (1998) Event-related potentials during a selective attention task with short interstimulus intervals in patients with schizophrenia. J Psychiatry Neurosci 23: 45-50
22. Javitt D C, Doneshka P, Grochowski S, Ritter W (1995) Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry 52: 550-558
23. Jeon Y W, Polich J (2003) Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 40: 684-701
24. Jonkman L M, Kemner C, Verbaten M N, Koelega H S, Camfferman G, Gaag R J v d, Buitelaar J K, van Engeland H (1997) Event-related potentials and performance of Attention-Deficit Hyperactivity Disorder: children and normal controls in auditory and visual selective attention tasks. Biol Psychiatry 41: 595-611
25. Juckel G, Mullerschubert A, Gaebel W, Hegerl U (1996) Residual symptoms and P300 in schizophrenic outpatients. Psychiatry Res 65: 23-32
26. Kahkonen S, Ahveninen J, Jaaskelainen I P, Kaakkola S, Näätänen R, Huttunen J, Pekkonen E (2001) Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study. Neuropsychopharmacology 25: 498-504
27. Kahn R S, Davidson M (1995) Dopamine in schizophrenia. In den Boer J A, Westenberg H G M, van Praag H M (eds), Advances in the Neurobiology of Schizophrenia: Wiley & Sons Ltd, New York, pp. 204-220
28. Karoumi B, Laurent A, Rosenfeld F, Rochet T, Brunon A M, Dalery J (2000) Alteration of event related potentials in siblings discordant for schizophrenia. Schizophr Res 41: 325-334
29. Kayser J, Bruder G E, Tenke C E, Stuart B K, Amador X F, Gorman J M (2001) Event-related brain potentials (ERPs) in schizophrenia for tonal and phonetic oddball tasks. Biol Psychiatry 49: 832-847
30. Kenemans J L, Molenaar P C, Verbaten M N, Slangen J L (1991) Removal of the ocular artifact from the EEG: a comparison of time and frequency domain methods with simulated and real data. Psychophysiology 28: 114-121
31. Kopitar Z, Vrhovac B, Povsic L, Plavsic F, Francetic I, Urbancic J (1991) The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine. Eur J Drug Metab Pharmacokinet 16: 177-181
32. Kraepelin E (1913) Psychiatrie, ein Lehrbuch für Studierende und Ärzte, 8th edn. Barth, J.A., Leipzig
33. Kruk Z L, Pycock C J (1991) Neurotransmitters and drugs, 3rd ed. Chapman and Hall, London
34. Laruelle M, Kegeles L S, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Annals New York Academy of Sciences 1003: 138-158
35. LeWitt P A, Nelson M V, Berchou R C, Galloway M P, Kesaree N, Kareti D, Schlick P (1989) Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 39: 45-53
36. Luthringer R, Rinaudo G, Toussaint M, Bailey P, Muller G, Muzet A, Macher J (1999) Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers. Neuropsychobiology 39: 49-56
37. McGhie A, Chapman J (1961) Disorders of attention and perception in early schizophrenia. Brit J Med Psychol 34: 103-116
38. McKetin R, Ward P B, Catts S V, Mattick R P, Bell J R (1999) Changes in auditory selective attention and event-related potentials following oral administration of D-amphetamine in humans. Neuropsychopharmacology 21: 380-390
39. Mervaala E, Alhainen K, Helkala E L, Partanen J, Jousmaki V, Vayrynen M, Heinonen E, Riekkinen P (1993) Electrophysiological and neuropsychological effects of a central alpha 2-antagonist atipamezole in healthy volunteers. Behav Brain Res 55: 85-91
40. Michie P T, Fox A M, Ward P B, Catts S V, Mcconaghy N (1990) Event-related potential indices of selective attention and cortical lateralization in schizophrenia. Psychophysiology 27: 209-227
41. Muller T J, Kalus P, Strik W K (2001) The neurophysiological meaning of auditory P300 in subtypes of schizophrenia. World J Biol Psychiatry 2: 9-17
42. Munson P L, Mueller R A, Breese G R (1995) Principles of Pharmacology, Basic Concepts and Clinical Applications. Chapman and Hall, New York
43. Näätänen R (1990) The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behav Brain Sci 13: 201-288
44. Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog Neurobiol 67: 53-83
45. Nishimura N, Ogura C, Ohta I (1995) Effects of the dopamine-related drug bromocriptine on event-related potentials and its relation to the law of initial value. Psychiatry Clin Neurosci 49: 79-86
46. Oishi M, Mochizuki Y, Hara M, Du C M, Takasu T (1996) Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism. Int J Neurosci 85: 147-154
47. Oranje B, Gispen-de Wied C C, Verbaten M N, Kahn R S (submitted) The effects of ketamine and haloperidol on human selective attention
48. Oranje B, Gispen-de Wied C C, Verbaten M N, Kahn R S (2004) Increasing dopaminergic activity in humans: effects of 1-dopa and bromocriptine on human sensory gating. J Psychopharmacol 18: 388-394
49. Oranje B, van Berckel B N M, Kemner C, van Ree J M, Kahn R S, Verbaten M N (2000) The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22: 293-302
50. Robertson D R, Higginson I, Macklin B S, Renwick A G, Waller D G, George C F (1991) The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol 31: 413-417
51. Roth W T, Cannon E H (1972) Some features of the auditory evoked response in schizophrenics. Arch Gen Psychiatry 27: 466-471
52. Sevostianov A, Fromm S, Nechaev V, Horwitz B, Braun A (2002) Effect of attention on central auditory processing: an fMRI study. Int J Neurosci 112: 587-606
53. Shelley A M, Catts S V, Ward P B, Andrews S, Mitchell P, Michie P, Mcconaghy N (1997) The effect of decreased catecholamine transmission on ERP indices of selective attention. Neuropsychopharmacology 16: 202-210
54. Shutara Y, Koga Y, Fujita K, Takeuchi H, Mochida M, Takemasa K (1996) An event-related potential study on the impairment of automatic processing of auditory input in schizophrenia. Brain Topogr 8: 285-289
55. Strandburg R J, Marsh J T, Brown W S, Asarnow R F, Guthrie D, Harper R, Nuechterlein K H (1999) Continuous-processing related ERPs in adult schizophrenia: continuity with childhood onset schizophrenia. Biol Psychiatry 45: 1356-1369
56. Strik W K, Dierks T, Kulke H, Maurer K, Fallgatter A (1996) The predictive value of P300-amplitudes in the course of schizophrenic disorders. J Neural Transm 103: 1351-1359
57. Takeshita S, Ogura C (1994) Effect of the dopamine D2 antagonist sulphide on event-related potentials and its relation to the law of initial value. Int J Psychophysiol 16: 99-106
58. Tandon R, Milner K, Jibson M D (1999) Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 60 (Suppl. 8): 21-28
59. Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J (1998) Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 44: 716-725
60. Ward P B, Catts S V, Fox A M, Michie P T, Mcconaghy N (1991) Auditory selective attention and event-related potentials in schizophrenia. Br J Psychiatry 158: 534-539
61. Woods D L (1990) The physiological basis of selective attention: implications of event-related potential studies. In Rohrbaugh J W, Parasuraman R, Johnson R Jr (eds), Event-related Brain Potentials: Basic Issues and Applications. Oxford University Press, New York, pp. 178-209
62. Yeh K C, August T F, Bush D F, Lasseter K C, Musson D G, Schwartz S, Smith M E, Titus D C (1989) Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39: 25-38